Doximity price target raised to $65 from $49 at Truist

Truist raised the firm’s price target on Doximity (DOCS) to $65 from $49 and keeps a Hold rating on the shares. The company posted results that were likely better than even the most optimistic investor expectations, as the strong outperformance in Q3 benefited from Doximity’s new integrated programs where customers committed larger deal sizes and longer commitment, the analyst tells investors in a research note. The firm adds however that FY25 benefited from market share gains as the pharma industry saw flight to quality.